Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity

Cell stem cell(2022)10.1016/j.stem.2021.12.007Source: DataRank Database

TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity is a research paper published in Cell stem cell (2022). On theSindex it has a DataRank of 0. It has been cited 62 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access62 citations

Download PDF

Cite:

Linked data & code

geo gen

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (38 grants)Impact (FWCI 8.13)OA: greenTopics (51)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (23)

María Guillamot ORCID,Jennifer Yeung ORCID,Jing Fang ORCID,Joshua Bennett,Bettina Nadorp ORCID

Live enrichment

PubMed:35045331 PMC:PMC8822959 OpenAlex:https://openalex.org/W4205143772

National Institutes of Health

Grant: R01CA216421

National Institutes of Health

Grant: R35HL135787

National Institutes of Health

Grant: L40HL143713

National Institutes of Health

Grant: R01CA190261

National Institutes of Health

Grant: 1RO1HL159175

National Institutes of Health

Grant: R01CA228135

National Institutes of Health

Grant: R01CA242020

National Institutes of Health

Grant: R01DK102759

National Institutes of Health

Grant: R01DK113639

National Institutes of Health

Grant: R01CA173636

National Institutes of Health

Grant: 1RO1CA266212

NHLBI NIH HHS

Grant: F32 HL149280

NCI NIH HHS

Grant: R01 CA266212

NCATS NIH HHS

Grant: UL1 TR001425

NCI NIH HHS

Grant: P30 CA008748

NIDDK NIH HHS

Grant: U54 DK126108

NCI NIH HHS

Grant: R01 CA271455

NHLBI NIH HHS

Grant: R01 HL159175

NCI NIH HHS

Grant: T32 CA117846

NIEHS NIH HHS

Grant: T32 ES007250

National Institutes of Health

Grant: 5R01CA242020-05

Targeting an RNA Binding Protein Network in Acute Myeloid Leukemia

National Institutes of Health

Grant: 5R01HL159175-04

Regulation of emergency hematopoiesis by the ubiquitin-proteasome system

National Institutes of Health

Grant: 1R01CA228135-01A1

Mechanisms of enhancer regulation in leukemia

National Institutes of Health

Grant: 5R01CA190261-03

The impact of chromosome 17p lesions on leukemogeneis and therapy response

National Institutes of Health

Grant: 5R01CA216421-05

The cohesin complex as a tumor suppressor in myeloid leukemia

National Institutes of Health

Grant: 1R01DK113639-01

Targeting IRAK1/4 in Myelodysplastic Syndromes

National Institutes of Health

Grant: 1R35HL135787-01

Decoding innate immune signaling in normal and myelodysplastic hematopoiesis

National Institutes of Health

Grant: 5R01CA173636-03

Role of TET2 mutations in malignant transformation and acute myeloid leukemia

National Institutes of Health

Grant: 1R01DK102759-01

Molecular Pathogenesis of MDS

Cincinnati Children’s Research Foundation

Gilead Sciences

Leukemia and Lymphoma Society

Waksman Foundation of Japan

American Society of Hematology

Mochida Memorial Foundation for Medical and Pharmaceutical Research

Japan Society for the Promotion of Science

Edward P. Evans Foundation

Uehara Memorial Foundation

FWCI

8.13

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: Elsevier Non-Commercial

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8822959

publisherhttps://api.elsevier.com/content/article/PII:S1934590921004914?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1934590921004914?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.stem.2021.12.007

Fields of Study

Acute Myeloid Leukemia ResearchUbiquitin and proteasome pathwaysHistone Deacetylase Inhibitors Research0301 basic medicine03 medical and health sciencesHematopoiesisHumansIntracellular Signaling Peptides and ProteinsLeukemia, Myeloid, AcuteMutationMyeloproliferative DisordersTNF Receptor-Associated Factor 6

MeSH Terms

HematopoiesisHumansMutationMyeloproliferative DisordersLeukemia, Myeloid, AcuteIntracellular Signaling Peptides and ProteinsTNF Receptor-Associated Factor 6

Keywords

BiologyMyeloid leukemiaCancer researchMyeloidUbiquitin ligaseHaematopoiesisEpigeneticsLeukemiaSuppressorUbiquitinStem cellGeneImmunologyCell biologyGeneticsUbiquitinationAMlInflammationMYCHematopoiesisMPNMDSTraf6Myeloid MalignanciesInnate Immune SignalingClonal HematopoiesisTNF Receptor-Associated Factor 6Leukemia, Myeloid, AcuteMyeloproliferative DisordersMutationIntracellular Signaling Peptides and ProteinsHumans

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity

FAIR Checklist

Authors (23)

Funding (38 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)